Patrick Keenan | Managing Director
Prevail Partners

Patrick Keenan, Managing Director, Prevail Partners

Patrick Keenan is the Managing Director of Prevail Partners, LLC, a life sciences investment firm focused on innovative clinical stage therapeutic, medical device and diagnostics companies. During his nine-year tenure, Prevail Partners has invested in over 30 private and public companies.  These portfolio companies have entered into licensing deals with over $2 billion in payments and completed several successful IPOs.  Patrick was previously in private law practice with a focus on intellectual property and was recognized as among Pennsylvania Super Lawyers™.  He has been a speaker at several healthcare conferences, including Stem Cell Summit 2016 and 2018, Bio Korea 2013, and others.  Patrick is a board member of Shimojani Inc. and the non-profit Peace of Mind Project.  He obtained his undergraduate degree from Stockton University and Juris Doctorate from Rutgers School of Law.


World Anti-Microbial Resistance Congress USA 2018 - Day 1 @ 11:30

VC Panel: Funding for innovative traditional drugs as well as non-traditional antibiotic development

  • Investing in traditional innovation in the antibiotic space
  • Non-traditional products and pipeline a private funders perspective.
  • What is the future of additional VC funding for both traditional and non-traditional antibiotics and innovation
last published: 18/Oct/18 13:55 GMT

back to speakers